INS and type 1 diabetes mellitus: In a small randomized, double-blind, placebo-controlled trial over a 12-week period, involving 40 T1D participants with an HbA1c level of at least 8% and a normal body mass index (BMI), liraglutide significantly reduced body weight and insulin requirements but did not improve glycemic control [29].